- Home
- Products
- Customized FluoroAb™
- PRLR
- Anti-PRLR MAb (Clone 2)-iFluor® 460 Succinimidyl Ester
Anti-PRLR MAb (Clone 2)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS8553)
This product is comprised of an Chimeric Anti-PRLR IgG1-kappa (Clone 2) labeled with iFluor® 460 Succinimidyl Ester. iFluor® 460 Succinimidyl Ester is a Green-fluorescent dye and it's excitation/emission is 403/427 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- PRLR
- Overview
- Chimeric Anti-PRLR IgG1-kappa (Clone 2)
- Species Reactivity
- Human
- Name
- iFluor® 460 Succinimidyl Ester
- Color
- Green
- Excitation⁄Emission (nm)
- 468/493
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS8553. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-050 | Anti-PRLR-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD40 MAb (Clone 15)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13489)
- Anti-RSV MAb (Clone 2)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10796)
- Anti-FLT1 MAb (Clone 1)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS1758)
- Anti-TNFRSF9 MAb (Clone 13)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10761)
- Anti-ERBB2 MAb (Clone 31)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13207)
- Crenezumab-iFluor 594 (CAT#: ADC-FL-116)
- Anti-CMV MAb (Clone 1)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14565)
- Anti-RTN4 MAb (Clone 2)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5303)
- Anti-CTLA4 MAb (Clone 14)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4322)
- Anti-ITGAL MAb (Clone 1)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS9876)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
